{"denoms":[{"counts":[{"groupId":"BG000","value":"12"}],"units":"Participants"}],"groups":[{"description":"Induction treatment cycles with rituximab, high-dose methotrexate and leucovorin will be administered every 2 weeks for 6 cycles. Two additional consolidation cycles of high-dose methotrexate without rituximab will be administered at 4 weeks and 8 weeks following completion of the combined therapy.\n\nMethotrexate: 6000 mg/m\\^2 will be administered by intravenous infusion over 4 hours after confirming that the recipient patients urine pH is within the range greater than or equal to 7 to less than or equal to 8, and urine output is greater than or equal to 100 mL/hour.\n\nRituximab: 375 mg/m\\^2 intravenous (IV) day 1 of each cycle prior to administration of high-dose methotrexate\n\nLeucovorin: Leucovorin calcium doses will be administered orally or by short intravenous (IV) infusion over 15 minutes","id":"BG000","title":"Rituximab, High-Dose Methotrexate & Leucovorin Treatment"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"12"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.01","value":"33.74"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"9"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"United States"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"5","upperLimit":"29","value":"22"}]}]}],"description":"The MMSE is scored out of a maximum of 30 points. A score of \\>25 is considered normal, with scores \\<25 indicating different levels of cognitive impairment: mild (21-24) moderate (10-20), and severe (0-10).","dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Median Baseline Mini Mental State Exam (MMSE) Score","unitOfMeasure":"score on a scale"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"1","upperLimit":"3","value":"2"}]}]}],"description":"ECOG Scale: 0 is fully active and able to carry on activities of daily living without restriction; 1 is restricted in physically strenuous activity but ambulatory, can perform light housework; 2 is ambulatory and able to perform self care but unable to carry out work activities; 3 is capable of limited self care and confined to bed or chair more than 50% of waking hours; 4 is completely disabled, unable to perform selfcare, and confined to bed or chair; and 5 is dead.","dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Median Baseline Eastern Cooperative Oncology Group (ECOG) Performance Status","unitOfMeasure":"scores on a scale"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0","upperLimit":"409","value":"16"}]}]}],"description":"Primary central nervous system lymphoma (PCNSL). PCNSL was biopsy confirmed or made by fludeoxyglucose positron emission tomography/cerebral spinal fluid Epstein Barr-Virus (EBV) viral load criteria.","dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Baseline Cluster of Differentiation (CD4) T Cell Count at PCNSL Diagnosis","unitOfMeasure":"cells/µL"}]}